L&G Pharma Breakthrough UCITS ETF (LON:BIOT)

Assets	16.92M
Expense Ratio	0.49%
PE Ratio	20.10
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+18.77%

Volume	306
Open	15.02
Previous Close	15.05
Day's Range	14.93 - 15.09
52-Week Low	12.17
52-Week High	16.15
Beta	0.55
Holdings	46
Inception Date	Jan 23, 2018

About BIOT

The L&G Pharma Breakthrough UCITS ETF is designed to mirror the financial performance generated by the Solactive Pharma Breakthrough Value Index.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: London Stock Exchange
• Ticker Symbol: BIOT
• Provider: L&G
• Index Tracked: Solactive Pharma Breakthrough Value Index

Performance

BIOT had a total return of 18.77% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.35%.

Top 10 Holdings

26.04% of assets

Name	Symbol	Weight
Basilea Pharmaceutica AG	BSLN	2.71%
Eisai Co., Ltd.	4523	2.66%
Genmab A/S	GMAB	2.63%
AstraZeneca PLC	AZN	2.63%
Halozyme Therapeutics, Inc.	HALO	2.61%
United Therapeutics Corporation	UTHR	2.59%
Recordati Industria Chimica e Farmaceutica S.p.A.	REC	2.56%
Agios Pharmaceuticals, Inc.	AGIO	2.56%
Ligand Pharmaceuticals Incorporated	LGND	2.54%
Nippon Shinyaku Co., Ltd.	4516	2.54%

Data Sources: S&P Global Market Intelligence, Financial Modeling Prep, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error